Save Medical Corp.

Save Medical Corp., established in May 2018, operates in the HealthTech sector, focusing on the development and distribution of medical device programs. The company was founded by Shotaro Asano, who currently serves as the Representative Director and President. His journey into digital health was shaped by his experience at Recruit Holdings, where he was involved in venture capital and business development in Silicon Valley, focusing on digital health investments. This exposure, coupled with his subsequent role as a business development director at the Japan Organization for Medical Device Development (JOMDD) and a Master of Public Health (MPH) from St. Luke's International University, provided him with a unique blend of business acumen and public health insight, leading to the creation of Save Medical.

The company is centered on creating Digital Therapeutics (DTx), which are software-based interventions designed to prevent, manage, or treat medical conditions. A primary area of focus has been the development of a medical device application for patients with Type 2 diabetes, which was the subject of Japan's first clinical trial for a diabetes app. In a strategic pivot, Save Medical has broadened its business model. While continuing its own product development, the firm now leverages its accumulated expertise to offer consulting services to other companies developing Software as a Medical Device (SaMD). This consultancy assists clients with business strategy, regulatory affairs, and the establishment of a Quality Management System (QMS), addressing a significant pain point for new entrants in the highly regulated medical device market.

Save Medical has also developed a portfolio of mobile applications aimed at general wellness and health management. These include "DripMate & DripGo," an app to assist with IV drip calculations; "SleepGate" for relaxation before sleep; "Lucent" for tracking wrist skin temperature via Apple Watch; and "PelviCare," a pelvic floor muscle training app. The company generates revenue through the development and sale of its medical device software and its consulting services for the SaMD industry. The company's client base includes pharmaceutical companies and other firms in the digital health space seeking to commercialize SaMD products. Having secured multiple rounds of venture capital funding since its seed round in 2018, the company is backed by investors such as TIS Inc., Spiral Capital, and Mitsubishi UFJ Capital.

Keywords: Digital Therapeutics, DTx, SaMD, Software as a Medical Device, HealthTech, MedTech, medical device software, mobile health applications, Type 2 diabetes treatment, QMS consulting, regulatory affairs, clinical trials, Shotaro Asano, digital health, medical app development, healthcare software, lifestyle-related diseases, IV drip calculation, sleep aid app, pelvic floor training, wrist temperature tracking